eligibility_summary
Adults (≥18) with consent and ≥3‑mo survival, CD20+ r/r B‑cell NHL with post‑SCT relapse or after ≥2L incl CD20+anthracycline, ECOG 0–2, measurable PET‑avid disease, adequate blood counts and renal/hepatic function, contraception. Exclude: CNS lymphoma, active autoimmune/GVHD, major CV disease/QTc prolongation/uncontrolled HTN, recent HSCT/cell/anticancer therapy, live vaccine/surgery, chronic steroids, other cancer/severe comorbidity, recent infection, active HBV/HCV/HIV/syphilis, severe allergy, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: AcNK-Sup003 cell injection—an adoptive cellular immunotherapy using cryopreserved, non–genetically modified NK cells whose surfaces are covalently, directionally conjugated (via one-step enzymatic linkage) to intact bispecific antibodies. Antibody specificity: CD19 and CD20. Mechanism: the tethered bispecific IgGs bridge NK cells to malignant B cells, providing dual-antigen recognition and stable immune-synapse formation, enhancing NK degranulation (perforin/granzyme) and Fc-mediated cytotoxicity/ADCC. Target cells/pathways: CD19+/CD20+ B‑cell lymphoma cells, NK cell cytotoxic and Fc receptor pathways within innate immunity. Trial: open-label, single-arm, dose-escalation (3×10^8 to 9×10^9 cells), up to three infusions per 28‑day cycle, in relapsed/refractory B‑NHL.